- Trials with a EudraCT protocol (31)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
31 result(s) found for: Platelet Activating Factor.
Displaying page 1 of 2.
EudraCT Number: 2010-023869-21 | Sponsor Protocol Number: ML25575 | Start Date*: 2011-02-09 | ||||||||||||||||
Sponsor Name:Roche Oy | ||||||||||||||||||
Full Title: A study of erlotinib (Tarceva®) treatment in patients with locally advanced or metastatic non-small cell lunf cancer who present activating mutations in the tyrosine kinase domain of the epidermal ... | ||||||||||||||||||
Medical condition: Locally advanced or metastatic non-small cell lung cancer with activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FI (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-002894-39 | Sponsor Protocol Number: 8273-CL-0302 | Start Date*: 2016-03-11 | ||||||||||||||||
Sponsor Name:Astellas Pharma Global Development, Inc. | ||||||||||||||||||
Full Title: An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer Tumors with EGFR Activating M... | ||||||||||||||||||
Medical condition: Non-small Cell Lung Cancer Tumors | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) HU (Completed) DE (Prematurely Ended) NL (Prematurely Ended) ES (Temporarily Halted) PT (Prematurely Ended) BE (Completed) FR (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-004328-12 | Sponsor Protocol Number: Europe | Start Date*: 2015-01-23 | |||||||||||
Sponsor Name:GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH | |||||||||||||
Full Title: Prospective validation of a predictive model of response to romiplostim in patients with IPSS low or intermediate-1 risk myelodysplastic syndrome (MDS) and thrombocytopenia - the EUROPE-trial | |||||||||||||
Medical condition: Patients with IPSS low or intermediate-1 risk myelodysplastic syndrome (MDS) and thrombocytopenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Ongoing) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003866-14 | Sponsor Protocol Number: APX005M-002 | Start Date*: 2019-02-28 | ||||||||||||||||
Sponsor Name:Apexigen, Inc. | ||||||||||||||||||
Full Title: A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastati... | ||||||||||||||||||
Medical condition: Non-small Cell Lung Cancer and Metastatic Melanoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) FR (Ongoing) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-005364-14 | Sponsor Protocol Number: IEO206 | Start Date*: 2016-04-26 | |||||||||||
Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA | |||||||||||||
Full Title: Phase II trial of Afatinib as induction treatment in patients with stage IIIA or stage IIIB N2 requiring neoadjuvant treatment for pN2 non squamous non small cell lung cancer (NSCLC) with EGFR-act... | |||||||||||||
Medical condition: Patients with stage IIIA or stage IIIB N2 requiring neoadjuvant treatment for pN2 non squamous non small cell lung cancer (NSCLC) with EGFR-activating mutations | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023892-24 | Sponsor Protocol Number: ML25514 | Start Date*: 2011-01-26 | ||||||||||||||||
Sponsor Name:ROCHE | ||||||||||||||||||
Full Title: Phase II, open-label study of erlotinib (Tarceva) treatment In patients with locally advanced or metastatic non-small-cell lung cancer who present activating mutations in the tyrosine kinase domain... | ||||||||||||||||||
Medical condition: Stage IIIB, IV non-small-cell lung cancer (NSCLC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-004810-16 | Sponsor Protocol Number: TPU-TAS-120-101 | Start Date*: 2014-04-10 | |||||||||||
Sponsor Name:Taiho Oncology Inc | |||||||||||||
Full Title: PHASE 1/2 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS HARBORING FGF/FGFR ABERRATIONS | |||||||||||||
Medical condition: Advanced solid tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) DE (Completed) NL (Ongoing) PT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022235-10 | Sponsor Protocol Number: ITCC-015/EWOG-MDS-Azacytidine-2010 | Start Date*: 2012-03-07 | ||||||||||||||||
Sponsor Name:Erasmus MC | ||||||||||||||||||
Full Title: A Phase I/II study of Azacitidine (Vidaza®) in pediatric patients with relapsed high-grade pediatric MDS or JMML | ||||||||||||||||||
Medical condition: Relapsed advanced Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leukemia (JMML) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) CZ (Completed) IT (Prematurely Ended) AT (Prematurely Ended) DE (Prematurely Ended) DK (Prematurely Ended) IE (Prematurely Ended) ES (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-003864-30 | Sponsor Protocol Number: APX005M-010 | Start Date*: 2019-02-08 | |||||||||||
Sponsor Name:Apexigen, Inc. | |||||||||||||
Full Title: A Study to Evaluate the Safety and efficacy of the CD40 Agonistic Antibody APX005M in Adults with Immunotherapy Naive Metastatic Melanoma | |||||||||||||
Medical condition: Unresectable or metastatic melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002675-29 | Sponsor Protocol Number: CC-486-MDS-006 | Start Date*: 2015-06-19 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A Phase 2, International, Multicenter, Single-arm, Open-label Study to Evaluate the Efficacy and Safety of CC-486 (oral azacitidine) in Subjects With Myelodysplastic Syndromes Who Fail to Achieve a... | |||||||||||||
Medical condition: Myelodysplastic syndrome (MDS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) GB (GB - no longer in EU/EEA) BE (Completed) ES (Ongoing) DE (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004559-38 | Sponsor Protocol Number: RG_12-101 | Start Date*: 2012-08-08 | ||||||||||||||||
Sponsor Name:University of Birmingham | ||||||||||||||||||
Full Title: A phase 2 study of the efficacy and safety of Deferasirox administered at early iron loading in patients with transfusion-dependent Myelodysplastic Syndromes. | ||||||||||||||||||
Medical condition: Iron overload in patients being treated for Myelodysplastic syndroms (MDS) by regular blood transfusions | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-000477-39 | Sponsor Protocol Number: AMLSG20-13 | Start Date*: 2016-01-29 | ||||||||||||||||
Sponsor Name:University Hospital Ulm | ||||||||||||||||||
Full Title: Dose Finding safety run in Phase followed by a randomized Phase II Trial of Intensive Chemotherapy With or Without Volasertib (BI 6727) Administered Prior or After Chemotherapy in Patients With New... | ||||||||||||||||||
Medical condition: patients with newly diagnosed high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-000212-28 | Sponsor Protocol Number: LOXO-RET-18036 | Start Date*: 2020-04-15 | ||||||||||||||||||||||||||
Sponsor Name:Loxo Oncology, Inc. | ||||||||||||||||||||||||||||
Full Title: A Phase 1/2 Study of the Oral RET Inhibitor LOXO-292 in Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors | ||||||||||||||||||||||||||||
Medical condition: Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: ES (Ongoing) FR (Ongoing) DE (Ongoing) IT (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004899-18 | Sponsor Protocol Number: LUSPLUS | Start Date*: 2021-09-17 | |||||||||||||||||||||
Sponsor Name:GWT-TUD GmbH | |||||||||||||||||||||||
Full Title: A phase IIIb, open-label, single arm study to evaluate the efficacy and safety of luspatercept in patients with lower-risk MDS and ring-sideroblastic phenotype (MDS-RS) | |||||||||||||||||||||||
Medical condition: Lower-risk myelodysplastic syndrome with ring-sideroblastic phenotype (MDS-RS) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Ongoing) AT (Ongoing) ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004839-23 | Sponsor Protocol Number: CA-4948-102 | Start Date*: 2023-02-09 | ||||||||||||||||
Sponsor Name:Curis, Inc | ||||||||||||||||||
Full Title: A Phase 1/2a, Open-Label Dose Escalation and Cohort Expansion Study of Orally Administered CA-4948(IRAK4i) as a Monotherapy in patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome a... | ||||||||||||||||||
Medical condition: Acute Myelogenous Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS). | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) PL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011513-24 | Sponsor Protocol Number: CC-5013-MDS-005 | Start Date*: 2009-12-14 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO COMPARE THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID®) VERSUS PLACEBO IN SUBJECTS WITH TRANSFUSION... | |||||||||||||
Medical condition: TRANSFUSION-DEPENDENT ANEMIA DUE TO IPSS LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES WITHOUT DELETION 5Q [31] AND UNRESPONSIVE OR REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENT | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Completed) DE (Completed) FR (Completed) CZ (Completed) AT (Completed) IT (Completed) PT (Completed) GB (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003704-39 | Sponsor Protocol Number: BAY88-8223/19781 | Start Date*: 2019-10-25 | |||||||||||
Sponsor Name:Bayer Consumer Care AG | |||||||||||||
Full Title: An open-label, multicenter, Phase 1/2 study of radium-223 dichloride in combination with pembrolizumab in participants with stage IV non-small cell lung cancer | |||||||||||||
Medical condition: Stage IV non-small cell lung cancer (NSCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) BE (Completed) NL (Completed) DE (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002549-39 | Sponsor Protocol Number: Ponatinib-1501 | Start Date*: 2020-12-07 | |||||||||||
Sponsor Name:Takeda Development Center Americas, Inc. | |||||||||||||
Full Title: A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lympho... | |||||||||||||
Medical condition: acute lymphoblastic leukemia | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing) CZ (Completed) NL (Ongoing) IT (Ongoing) PL (Completed) PT (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024061-48 | Sponsor Protocol Number: ML25423 | Start Date*: 2011-05-25 | ||||||||||||||||||||||||||
Sponsor Name:Roche Bulgaria EOOD | ||||||||||||||||||||||||||||
Full Title: Phase II, open-label study of erlotinib (Tarceva®) treatment in patients with locally advanced, metastatic or recurrent non-small cell lung cancer who present activating mutations in the tyrosine k... | ||||||||||||||||||||||||||||
Medical condition: Locally advanced or metastatic NSCLC of stage IIIb or IV or recurrent NSCLC | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: BG (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-004873-29 | Sponsor Protocol Number: SGNTUC-019 | Start Date*: 2021-05-31 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Seagen Inc. | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: BE (Trial now transitioned) NL (Ongoing) DE (Trial now transitioned) PL (Completed) IT (Ongoing) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.